Typewriter secures $56M for non-viral gene therapy platform
Gene therapy startup Typewriter has raised a $56 million Series A to advance its non-viral delivery method. The approach avoids viral vectors, which have faced scrutiny over safety concerns. The funding will support further development of its platform.
Sources: msn.com
“The raise underscores growing investor interest in alternatives to viral vectors, as safety and scalability concerns persist in gene therapy.”
Read the original reporting
The outlets below did the original reporting.
Related briefs
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.